{"DataElement":{"publicId":"2195286","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Hydrocephalus Grade","preferredDefinition":"in CTC category Neurology, assessment of the severity of a hydrocephalus adverse event using a graded scale.","longName":"CTC_AE_HYDROCEPH_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2195284","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Hydrocephalus","preferredDefinition":"information related to the CTC adverse event of hydrocephalus.","longName":"CTC_AE_HYDROCEPHALUS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2195282","version":"1","preferredName":"Hydrocephalus","preferredDefinition":"Excessive accumulation of cerebrospinal fluid within the cranium which may be associated with dilation of cerebral ventricles, INTRACRANIAL HYPERTENSION; HEADACHE; lethargy; URINARY INCONTINENCE; and ATAXIA (and in infants macrocephaly). This condition may be caused by obstruction of cerebrospinal fluid pathways due to neurologic abnormalities, INTRACRANIAL HEMORRHAGES; CENTRAL NERVOUS SYSTEM INFECTIONS; BRAIN NEOPLASMS; CRANIOCEREBRAL TRAUMA; and other conditions. Impaired resorption of cerebrospinal fluid from the arachnoid villi results in a communicating form of hydrocephalus. Hydrocephalus ex-vacuo refers to ventricular dilation that occurs as a result of brain substance loss from CEREBRAL INFARCTION and other conditions.","longName":"Hydrocephalus","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Hydrocephalus","conceptCode":"C3111","definition":"A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC63A462-AFCB-05FA-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC63A462-AFD1-05FA-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2195285","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Hydrocephalus Grade","preferredDefinition":"in CTC category Neurology, assessment of the severity of a hydrocephalus adverse event using a graded scale.","longName":"CTC_AE_HYDROCEPH_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED19D04B-F616-1F8B-E034-0003BA3F9857","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Asymptomatic, radiographic findings only ","ValueMeaning":{"publicId":"2566432","version":"1","preferredName":"Asymptomatic, radiographic findings only ","longName":"2566432","preferredDefinition":"Asymptomatic, radiographic findings only ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D08D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-11","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED19D04B-F618-1F8B-E034-0003BA3F9857","beginDate":"2002-10-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Mild to moderate symptoms not interfering with ADL","ValueMeaning":{"publicId":"2572761","version":"1","preferredName":"Mild to moderate symptoms not interfering with ADL","longName":"2572761","preferredDefinition":"Mild to moderate symptoms not interfering with ADL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E946-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SHIDED","dateModified":"2005-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED19D04B-F61B-1F8B-E034-0003BA3F9857","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Severe symptoms or neurological deficit interfering with ADL","ValueMeaning":{"publicId":"2572762","version":"1","preferredName":"Severe symptoms or neurological deficit interfering with ADL","longName":"2572762","preferredDefinition":"Severe symptoms or neurological deficit interfering with ADL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E947-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SHIDED","dateModified":"2005-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED19D04B-F61F-1F8B-E034-0003BA3F9857","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"Disabling","ValueMeaning":{"publicId":"2566348","version":"1","preferredName":"Disabling","longName":"2566348","preferredDefinition":"Disabling","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D039-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED19D04B-F622-1F8B-E034-0003BA3F9857","beginDate":"2002-10-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2567604","version":"1","preferredName":"Death","longName":"2567604","preferredDefinition":"The cessation of life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D521-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"COOPERM","dateModified":"2015-11-24","changeDescription":"Added the NCIt concept definition as the System Generated definition per request by NMDP. mc 11/24/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED19D40E-56AF-1F69-E034-0003BA3F9857","beginDate":"2002-10-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED1A9844-CAFC-369D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Hydrocephal","type":"Preferred Question Text","description":"CTC Adverse Event Hydrocephalus Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Hydrocephalus Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ED19D04B-F602-1F8B-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-07","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}